Not Too ATTRACTive Data For Catheter Thrombolysis In Combatting Post-Thrombotic Syndrome
Executive Summary
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
You may also be interested in...
Penumbra Continues Push Into Peripheral Therapies
Penumbra Inc. continues its push into peripheral therapies with the recent US introduction of the POD Packing Coil, designed to occlude arteries and veins in conjunction with the company's Ruby and POD (Penumbra Occlusion Device) embolization products for the treatment of peripheral vascular conditions such as aneurysms and fistulas. The POD Packing coil, which earned a 510(k) in 2015 along with a neurovascular version of the device, grew out of the platinum coil technologies used to treat brain aneurysm.
Boston Scientific Cleared For Next-Gen Deep Vein Thrombosis Catheter
A year after Boston Sci bought Bayer's interventional unit, Medrad, the company says it has received a 510(k) clearance for its ZelanteDVT catheter to be used with its AngioJet Ultra Console to treat deep vein thrombosis as mechanical – rather than drug – DVT treatments are gaining more attention.
“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business
Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how Vyrsa supports Nevro's strategy in this growing market.